Illumina Announces Partnerships to Automate TruSeq® and Nextera® Sample
Automation Methods Developed By Leading Vendors Will Enable Customers to
Accelerate Testing and Discovery
SAN DIEGO -- May 15, 2013
Illumina, Inc. (NASDAQ:ILMN) today announced it is collaborating with leading
providers of liquid handling robotic platforms to develop automation methods
for its best-in-class TruSeq and Nextera Sample Preparation kits. Initial
partners in this effort are Beckman Coulter Life Sciences, Eppendorf, Hamilton
Robotics, PerkinElmer, and Tecan.
These partnerships, and the resulting methods, reflect Illumina's commitment
to creating the simplest, most efficient next-generation sequencing (NGS)
workflows, and represent an important step towards enabling complete,
end-to-end solutions for customers.
“We are excited to work with the top automation providers to deliver solutions
that can be readily implemented in the lab, thus saving time for our customers
and making automation much more accessible," said Christian Henry, Senior Vice
President and General Manager of Illumina’s Genomic Solutions business.
“TruSeq and Nextera sample preparation kits are designed with master-mixed
reagents and simplified protocols to facilitate automation. In the long term,
the new methods will allow more samples to be run simultaneously and with
fewer errors, while freeing up resources so that customers can focus on their
Under the agreements, sample preparation kits sold by Illumina will be
automated by the partners, who will develop, distribute and install the
methods on customers' robots, as well as provide technical support. Illumina
will assist during development, testing and promotion of the methods. Methods
for TruSeq RNA Sample Preparation kits will be available by end of Q2 2013,
with automation methods for additional TruSeq and Nextera kits to follow.
For more information, visit www.illumina.com/automation.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paying the way for molecular
medicine and ultimately transforming healthcare.
This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are not
limited to, statements we make regarding the expected availability dates for
sample preparation kit automation methods. Important factors that could cause
actual results to differ materially from those in any forward-looking
statements include challenges inherent in developing, manufacturing, and
launching new products and services and the other factors that are detailed in
our filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
Press spacebar to pause and continue. Press esc to stop.